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Abstract
Background & Aims: Glutathione S-transferase (GST) plays a key role in detoxification of xenobiotics and consequently polymorphisms 
of GST gene may determine susceptibility to several types of metabolic disorders and endue free radicals elimination. There is still no 
clear evidence of GSTM1 and GSTT1 genes association with gastroesophageal reflux disease (GeRD) complication by diabetes mellitus 
type 2 (DM2). Therefore, the aim of the study is to establish the difference in null GSTM1 and GSTT1 genes polymorphisms between 
GeRD patients with and without diabetes in Northern Bukovina (Western Ukraine).
Methods: The GSTM1 and GSTT1 genes’ polymorphisms were analyzed using a multiplex polymerase chain reaction (PcR) in 33 
patients with GeRD and DM2 and 17 controls with GeRD without DM2. 
Results: It was found that there is no significant difference (p>0.05) in GSTM1/GSTT1 haplotypes distribution between observed 
groups. Neither GSTM1 null mutation, nor GSTT1 null mutation increase the risk of GeRD and DM2 incidence, depending on types 
and severity of esophagitis (OR=0.48-2.03, 95% cI=0.06-8.66, p>0.05). Almost half (48.0%) of patients with GeRD have mutation in the 
studied GST genes promoters areas. every third patient (36.0%) is the carrier of a mutant 0/0-genotype of GSTM1 gene in haplotype, 
while the combination of homozygous GSTT1 gene mutations observed 2.6 times less often (14.0%). Linked mutation is absent in 
52.0% of patients. No statistically significant associations were observed between the haplotypes of GSTM1 and GSTT1 genes and 
GeRD/DM2 presence, depending on smoking, age, gender, and type of esophagitis. 
Conclusion: Presence of homozygous deletion in the promoters’ areas of GSTT1 and/or GSTM1 genes in haplotype does not 
significantly increase the risk of DM2 in GeRD patients.
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Introduction
Gastroesophageal reflux disease (GERD) is an important 
common disease in with multi-factorial etiology, involving 
complex interactions between genetic and environmental factors, 
and individual susceptibility to environmental risk factors. This 
difference in susceptibility may result from inherited polymorphisms 
in various genes controlling enzymatic metabolism, detoxification 
processes, repair of DNA damage and cell cycle.1-3 The glutathione 
S-transferases (GSTs) are genes of phase II metabolic enzymes 
superfamily that play the general function in conjugating 
glutathione with electrophilic substances capable of generating 
free radicals.4 Also, they can be involved in the development of 
cardio-vascular diseases and diabetic mellitus complications,5,6 
alcoholic liver cirrhosis,7 non-alcoholic fatty liver disease,8 with 
conflicting data about their role in initiation of carcinogenesis,9-11 
determining peroxidase activity and inflammatory responses in 
patients with Rheumatoid Arthritis, etc.12 GSTs genes mutations 
are associated with reduced activity of GSTs and are of great 
interest for determining the disease susceptibility.13 The GSTs’ 
isoenzymes are divided into at least five major classes (α, μ, π, θ, 
ζ).14 Clinically significant polymorphisms have been detected in 
the genes encoding for GSTA1 (α class) GSTM1 (μ class), GSTP1 
(π class), GSTT1 (θ class) and GSTZ1 (ζ class). Among them, the 
GSTM1, GSTP1 and GSTT1 genotypes have been extensively 
studied during recent years for their potential modulating role in 
individual susceptibility to environmentally-induced diseases. The 
GSTM1 gene in chromosome 1p13, GSTT1 gene in chromosome 
22q11.2 – according to three alleles, can be grouped into two 
classes: GSTM1-null, GSTT1-null homozygote for the null allele 
(GSTM1-0, GSTT1-0) – nonfunctional class and GSTM1-1, 
with at least one of the GSTM1a, or GSTM1b alleles, or GSTT1-
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1 – functional class.15 Polymorphic deletion variants in the 
GSTM1 and GSTT1 genes produce a functional enzyme (non-
deletion alleles or heterozygous deletion, GSTM1-1 and GSTT1-
1) or result in the complete absence of the enzyme (homozygous 
deletion alleles, GSTM1-null and GSTT1-null).16 GSTM1-null 
and GSTT1-null variants in some studies were associated with 
increased susceptibility to inflammatory processes, male infertility, 
and increased risk of cancers or pre-malignant conditions.15,17-21 
However, these studies have yielded contradictory results. We did 
not find reliable data of GSTM1 and GSTT1 genes association 
with GERD. 
Therefore, we performed an investigation of deletion (null) 
polymorphism of GSTM1 and GSTT1 genes’ alleles, genotypes 
and haplotypes frequency in GERD patients with diabetes 
mellitus type 2 (DM2). The aim of our study was to establish 
the difference in null GSTM1 and GSTT1 genes polymorphisms 
between GERD patients with and without diabetes in Northern 
Bukovina (Western Ukraine).
Patients and methods
Study was performed in compliance with the Council of 
Europe Convention on Human Rights and Biomedicine and 
recommendations of the Committee on Bioethics of the Ministry 
of Health of Ukraine. Patients’ Examination Cards and Patients’ 
Informed Consent Forms were approved by the Biomedical Ethics 
Commission of Bukovina State Medical University, Ministry of 
Health of Ukraine (Chernivtsi, Ukraine). All enrolled patients were 
treated in the Gastroenterology Department, Regional Clinical 
Hospital (Chernivtsi, Ukraine) during January-December, 2012. 
Genetic bench study performed in the laboratory of Medical 
Biology and Genetics Department of Bukovina State Medical 
University. After screening (matching inclusion/exclusion criteria) 
50 GERD patients were selected for further examination.
Inclusion criteria
Patients with GERD typical symptoms for 6 months (heartburn 
and/or acid regurgitation minimum twice weekly); atypical 
symptoms (epigastric pain, nausea, belching, halitosis, pseudo-
angina pain); or with erosive GERD discovered during 
endoscopic examination (reflux esophagitis); or at the stage of 
GERD complications (peptic stenosis of the esophagus, digestive 
hemorrhage).22-24 Patients with GERD and only with type 2 
diabetes mellitus (DM2) were included.
Exclusion criteria
We excluded patients from the study treated surgically for GERD 
or presenting symptoms of GERD once a week or less frequently; 
or presenting undercurrent factors that can cause disorders like 
bulimia or anorexia; professionals exposure to toxic agents (acid 
fumes and aerosols used in industry); pregnant women or in 
lactation period; subjects with psychological disorders; patients 
with DM1.
Diagnosis of GERD
15 patients of the study and control groups were newly diagnosed 
patients observed at the Gastroenterology Department, Regional 
Hospital; 35 patients – with chronic GERD. Gastro-esophageal 
reflux disease was diagnosed by esophagogastroduodenoscopy 
and esophageal pH-metry according to Montreal Consensus.22 All 
enrolled patients underwent endoscopy.
Genomic DNA was extracted from peripheral blood leukocytes 
using the “DNA-sorb-B” test system, with primers specific to the 
genes’ alleles.25 Detection of GSTM1 and GSTT1 genes deletions 
was performed by the multiplex polymerase chain reaction (PCR) 
according to the manufacturer’s protocol. Allele-specific primers 
were used in the PCR (Table 1). The PCR was performed in a 
total volume of 25 µL containing: 200 ng of isolated DNA, 65 









), 0.8×SYBR Red, 0.2 mМ of each dNTPs (dATP, 
dTTP, dGTP and dCTP), 0.3 µМ of each primer for GSTM1 
and albumin, 0.3 µМ of each primer for GSTT1 and 0.5 of 
thermostable Taq polymerase (Applied Biosystems, USA). The 
amplification conditions were subjected to initial denaturation at 
94 °C for 10 min; 35 cycles consisting of denaturation at 94 °C for 
1 min, primer annealing at 60 °C for 30 s and DNA elongation 
at 72 °C for 45 s; the final DNA elongation was at 72 °C for 10 
min. The multiplex PCR products (GSTM1-219 bp, GSTT1-
459 bp and albumine-350 bp) were separated by horizontal 
electrophoresis on 3% agarose gels, containing 4 µL of ethidium-
bromide and visualized by in the presence of molecular mass 
ladder (100-1000 bp) using a UV transilluminatior (Nyxtechnic, 
USA). Both GSTM1 and GSTT1 products were categorized as 
having either a non-null or null (homozygous deletion) genotype 
(Fig. 1). 
Statistical analysis
Statistical analysis was performed using Statistica 7.0 (StatSoft Inc, 
USA) software. p value and odds ratio (OR), with 95% confidence 
interval (CI) using a chi-square test were determined for the 
calculated frequencies of each allele, genotype and haplotypes. 
Risk ratios (RR) were estimated by OR. Adjusted OR and 95% 
CI were estimated for the association between the severe erosive 
esophagitis of II-III stages, DM2 and genetic polymorphism. p 
values ≤0.05 were considered statistically significant.
Results
The prospective study included 50 patients with GERD: study 
group – 33 patients with GERD + compensated DM2, among 
them – 16 patients with GERD and erosive esophagitis of I-III 
severity stages + compensated DM2 and 17 patients with GERD, 
non-erosive esophagitis + compensated DM2; control group – 17 
patients with GERD without DM2, among them – 7 patients with 
GERD and erosive esophagitis of I-III severity stages, 10 subjects 
– GERD and non-erosive esophagitis. Duration of GERD varied 
from 1 to 8 years (mean 5.69±1.03 years).
Detection of GSTM1 deletion and GSTT1 deletion was 
performed in 33 patients with GERD and DM2 (study group) 
and 17 patients with GERD and without DM2 as control group. 
Deletion of the GSTM1 gene was detected in 12 (36.4%) study 
group patients and in 6 controls (35.3%) (p>0.05), while the 
GSTT1 gene deletion polymorphism was detected in 5 study 
group patients (15.2%) and in 2 controls (11.8%) (p>0.05). 
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The overall frequency of GSTM1 null genotype was 1.75 times 
lower in study group compared with non-null GSTM1 (c2=4.91, 
р=0.027). There was no significant difference within the control 
group (c2=2.94, р>0,05). 
The number of study group patients with non-null GSTT1 
was 5,6 times higher than with null GSTT1 (c2=32.1, р<0.0001). 
Similarly, non-null GSTT1 prevailed (7.5 times) in control group 
(c2=19.9, p<0.0001). 
Both deletions were present only in 1 study group patient 
(3.0%) and was not found in control (Table 2).
Thus, almost half (48.0%) of patients with GERD have a 
mutation in the promoter area of  the studied GST genes. Every 
third patient (36.0%) is the carrier of a mutant 0/0-genotype of 
GSTM1 gene in haplotype, while the combination of homozygous 
GSTT1 gene mutations observed  2.6 times less (14.0%). Linked 
mutation is absent in 52.0% of patients.
No significant differences were found in distribution of 
GSTM1 and GSTT1 haplotypes between both groups. Neither 
GSTM1 null mutation, nor GSTT1 null mutation increase the 
risk of GERD and DM2 incidence, independently on types 
and severity of esophagitis (OR=0.48-2.03, 95% CI=0.06-8.66, 
p>0.05).
The frequency of GERD and non-erosive esophagitis did not 
depend on the haplotypes and concomitant DM2, whereas non-
erosive esophagitis was the most frequent pathology among the 
patients: 17 (34.0%) in study group and 10 (20.0%) in control. 
Combination of functional (1) alleles of both genes in haplotypes 
associated with more often presence of GERD and non-severe 
erosive esophagitis I stage (26.9%). The presence of GSTM1 
0/0 mutant homozygote in haplotypes (GSTT1+/GSTM1–) is 
accompanied by an increase the number of patients with GERD, 
DM and erosive esophagitis II stage (23.5%) versus GSTM1+/
GSTT1 0/0 carriers (16.7%, c2=5.48, p=0.041).
No statistically significant associations between the haplotypes 
of GSTM1 and GSTT1 genes and GERD/DM2 presence were 
observed, depending on smoking. Similarly, age, gender, smoking 
habits, and type of esophagitis did not associate with the risk of 
Figure 1. electrophoregramm of human DNA PcR products amplification 
of glutathione-S-transferase classes T1 (GSTT1) and M1 (GSTM1) genes 
polymorphism. M – Marker GeneRulerTM – DNA Ladder (1000-100 bp); lines 1, 
3, 6, 8 – homozygous deletion (0/0) in GSTM1 gene (null genotype); lines 2, 7, 
11 – positive (non-null) gemotype in both genes GSTT1 and GSTM1 (presence 
of functional 1 alelle); lines 5, 9, 10 – homozygous deletion (0/0) in GSTT1 
gene (null genotype); line 4 – positive PcR control.









GERD/DM2 (Table 3). 
Presence of homozygous deletion in the promoter areas of 
GSTT1 and GSTM1 haplotypes did not significantly increase the 
risk of comorbid condition DM2 in GERD patients.
Discussion
GERD and DM2 are heterogeneous disorders, with various 
genetic and environmental factors like diet and changes of 
microbiota26 contributing to the reflux of stomach contents 
causing troublesome symptoms and/or complications (erosive 
esophagitis, etc) and disorders in glucose/insulin homeostasis. In 
our study, we analyzed two different genes (GSTM1 and GSTT1) 
in GERD patients with and without DM2. 
Deletions of GSTM1 and GSTT1 genes cause an imbalance 
of pro-oxidants and antioxidants in esophageal sphincter tissue, 
influence glucose metabolism, insulin-resistance that could play 
a role in the etiology of both GERD and DM2. Inter-individual 
variability in GST enzymatic activity can influence the increased 
susceptibility to DM2, especially in those with environmental 
determinants, pernicious habits, obesity, etc.4,8,14,27,28  
The variability in the distribution of the null genotypes 
of GSTM1 and GSTT1, due to total or partial gene deletion 
resulting in the lack of the active enzyme, has been reported 
in different populations.27-31 Kala Z et al.32 hypothesized that 
polymorphisms in genes for detoxifying enzymes (GSTM1, 
GSTT1 and GSTP1) could influence susceptibility to reflux 
esophagitis (RE) and Barrett’s esophagus (BE) (the most common 
esophageal complications of GERD). The GSTM1 and GSTT1 
genes did not show any relationship with reflux disease, but the 
GSTP1 gene might be one of the risk factors associated with 
susceptibility to RE, especially to BE. Liu B et al.33 performed case-
control study (109 patients with RE, 97 patients with nonerosive 
reflux disease (NERD) and 97 normal controls) and proved 
that the subjects with GSTT1 and GSTM1 polymorphisms did 
not show any correlation with high risk for RE or NERD. No 
significant interactions were identified between the variant GSTs 
and cigarette smoking, or alcohol drinking and subtype of RE. In 
our study similarly GSTM1 and GSTT1 genes did not associated 
to GERD with or without DM2, regardless smoking. The 
association of GSTM1 and GSTT1 genetic polymorphism with 
GERD, erosive esophagitis and DM2 in west-Ukrainian patients 
was studied for the first time. 
DNA damage and mutation in detoxification enzymes, 
including the GST, is a well-established risk factor for tobacco-
related diseases. In the current study, we evaluated interaction 
between GSTM1/GSTT1 genotype and smoking in GERD+DM2 
cases and control, it was found that smoking does not significantly 
associate with the risk of GERD and DM2 either in GSTM1 / 
GSTT1-positive or null genotype. Otherwise, Casson AG et al.34 
reported that cigarette smoking is an independent risk factor for 
esophageal adenocarcinoma (EADC), especially when cigarette 
exposure was greater than 30 pack-years (OR=6.11, 95% CI=2.2-
17.32; p=0.001). The strong association between smoking and 
EADC was seen preferentially in patients with the active allele 
of either GSTM1 (OR=7.9, 95% CI=1.14-54.76; p=0.003) or 
GSTT1 (OR=3.2, 95% CI=1.23-8.35; p=0.004). Kim SJ et al.35 
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found that smokers with GSTM1-positive genotype in cases of 
coronary artery disease (CAD) were at approximately 1.21-fold 
higher risk of CAD and it was slightly higher with GSTM1/
T1-null genotype compared to non-smokers with GSTM1/T1-
positive genotype. 
Many studies assessed the associations between GSTM1/
GSTT1 null genotypes and DM risk but reported dissimilar 
results in populations, races, or ethic’s groups.36-39 Zhang J et 
al.28 performed meta-analysis of GSTM1/GSTT1 null genotypes 
associations with DM risk (11 publications, a total of 2577 cases 
and 4572 controls). Meta-analyses indicated that null genotypes 
of GSTM1/GSTT1 and dual null genotype of GSTM1/GSTT1 
were associated with increased risk of DM (GSTM1: OR 
random-effects=1.60, 95% CI=1.10-2.34, POR=0.014; GSTT1: 
OR random-effects=1.47, 95% CI=1.12-1.92, POR=0.005; 
GSTM1-GSTT1: OR fixed-effects=1.83, 95% CI=1.30-2.59, 
POR=0.001). This meta-analysis suggests null genotypes of 
GSTM1/GSTT1 and dual null genotype of GSTM1/GSTT1 are 
potential biomarkers of DM. However, exact mechanism of how 
presence of the null genotype increases risk of DM is not clear, yet. 
Similarly, it is not clear how null genotype influences pathogenesis 
of GERD and it complications. 
The GSTM1 null genotype frequencies vary from 38% to 67% 
in European populations, from 33% to 63% in Asians and from 
22% to 35% in Africans and African-Americans.29,40 In Brazilian 
urban populations, the GSTM1 null phenotype frequency varies 
from 46% to 49%, but in Brazilian Amerindian population – 
from 0 to 43%.27,41 Significant differences in GSTT1 null allele 
frequencies were observed between Caucasian, Asian, African 
and African American populations.42 Korean population showed 
higher frequency of  GSTT1 null allele (45.3%) compared with 
the white Americans (20.4%), African Americans (21.8%), 
Mexican-Americans (9.7%) and Turkish populations (10.8%-
28.3%).42-44. The GSTT1 null genotype frequencies vary 
0-19.8% in European populations, 3%-39% in Asians.30,41,42,44 
The prevalence of GSTM1 and GSTT1 null allele in the present 
study ranges from 35.3 to 36.4% for GSTM1 and from 11.8% 
to 15.2% for GSTT1, which is almost similar to the frequencies 
reported in Caucasians.
In conclusion, our finding may be an important contribution 
towards the identification of the role of genetic polymorphism 
of GST interactions for GERD+DM2 risk. Our results suggest 
that GSTM1 and GSTT1 null genotype has no association with 
the risk of DM2 in West-Ukrainian GERD patients’ regardless 
their smoking status. Further studies including examination of 
other genotypes and genes involved either in metabolic process 
or detoxification are anticipated to improve our ability to find 
genetic factors contributing to DM or/and GERD susceptibility.  
Table 1. Primer sequences for GSTM1 and GSTT1 genes SNPs
SNP locus Primers Primer sequences (5’-3’) Size of fragments, bp
GSTM1 Forward 5’GGTcААGGАcАTcАTАGАcGАGАА3’ 219
Reverse 5’cTcАGGАGАААcTGААGccААА3’
GSTT1 Forward 5’GcTАGTTGcTGААGTccTGcTTА3’ 459
Reverse 5’cTTGGccTTcАGААTGАccT3’
ALB Forward 5’TGGGTGcTАGАGGTАTААTcG3’ 350
Reverse 5’TTАGАGGААGcTGGGTААGАG3’
ALB, Part of the albumin gene, as an internal amplification control; SNP, single-nucleotide polymorphism.
Table 2. Distribution of GSTM1 and GSTT1 genotypes in observed subjects
Combination of GSTМ1 та GSTТ1 genotypes Study group, n=33 (%) Control group, n=17 (%) OR 95% CI  p-value
GSTM1+/GSTT1+, n=26 17 (51.5) 9 (52.9) 0.97 0.36-2.64 >0,05
GSTM1+/GSTT1 –, n=6 4 (12.1) 2 (11.8) 1.03 0.17-6.20 >0,05
GSTT1+/GSTM1–, n=17 11 (33.3) 6 (35.3) 0.94 0.30-2.99 >0,05
GSTT1–/GSTM1 – n=1 1 (3.0) N/A – – –
“+”, presence of functional allele (wild type) of GSTM1, GSTT1 genes; “–”, null (0/0) genotype (mutant type); n (%), number (percentage); N/A, not available..
Table 3. Association between haplotypes of GSTM1 and GSTT1 genes and GeRD / DM2 present depending on age, gender and smoking status
No. Potential risk factors Case, n=33 (%) Control, n=17 (%) OR (95%СІ) p-value
1 Age, years <60 28 (84.8) 14 (82.4) 0.83 (0.17-3.99) >0.05
≥60 5 (15.2) 3 (17.6)
2 Gender Male 15 (45.5) 6 (35.3) 1.53 (0.46-5.11) >0.05
Female 18 (54.5) 11 (64.7)
3 Smoking Yes 10 (30.3) 6 (35.3) 0.80 (0.23-2.76) >0.05
No 23 (69.7) 11 (64.7)
4 esophagitis erosive 16 (48.5) 7 (41.2) 1.34 (0.41-4.39) >0.05
Non-erosive 17 (51.5) 10 (58.8)
OR, odds ratio; OR (95%cІ), OR confidence interval.
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Limitations of the study
The present study was limited by a number of enrolled subjects; 
absence of individuals without GERD; patients were not all at 
the same stage of GERD; GSTP1 gene polymorphisms were not 
evaluated.
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